Chandan Healthcare has entered an exclusive partnership with Jeena Sikho Lifecare to establish diagnostic centres in all current and upcoming Jeena Sikho hospitals nationwide. Concurrently, the company approved the preferential issue of up to 4.45 million fully convertible equity warrants, enhancing capital for expansion.
Chandan Healthcare Ltd has announced a strategic and exclusive partnership with Jeena Sikho Lifecare Ltd aimed at establishing diagnostic centres across all existing and upcoming Jeena Sikho hospitals and clinics throughout India. This alliance positions Chandan Healthcare as the sole diagnostic service provider for Jeena Sikho Lifecare’s extensive hospital network, bolstering its footprint in healthcare diagnostics.
Key highlights of this partnership include:
-
Exclusive diagnostic rights for Chandan Healthcare at all Jeena Sikho facilities, enabling integrated and standardized diagnostic services.
-
Expansion of diagnostic capabilities to a growing number of hospital venues, enhancing patient access to efficient testing and diagnostic services.
-
Strengthening of healthcare delivery through collaboration between leading diagnostic and hospital service providers.
In a parallel development at the company’s Board meeting held on October 10, 2025, Chandan Healthcare approved a preferential basis issue of up to 44,50,000 fully convertible equity warrants. These warrants are convertible into equity shares at an issue price to be determined following regulations stipulated by SEBI and subject to shareholder and regulatory approvals.
Additional points from the board meeting included:
An increase in authorized share capital from Rs 25 crore to Rs 30 crore, facilitating the issuance of new shares corresponding to the warrants.
Appointment of a practicing company secretary as scrutinizer for fair conduct of the e-voting process during the Extraordinary General Meeting (EGM) to approve the preferential issue.
Steps towards strengthening capital structure to support the company’s growth initiatives including the new partnership’s expansion plans.
Chandan Healthcare, a leader in diagnostics with over 50 diagnostic centres and 500 collection points across multiple states, is set to leverage this partnership to enhance diagnostic services availability. Coupled with the preferential warrant issue, the company is proactively positioning itself for accelerated growth and expansion in the healthcare sector.
This collaboration highlights both companies’ commitment to improving healthcare outcomes through accessible, high-quality diagnostics and integrated care delivery.
Sources: National Stock Exchange of India official releases, Chandan Healthcare Ltd Board Meeting outcome disclosures dated October 10, 2025